UK life science A new life science campus has been approved to start construction in the UK.
According to a release, UBS Asset Management and the Reef Group, a UK-based developer of life science facilities, have gotten approval to start construction on a new £900 million ($1.1 billion) life sciences hub at the Stevenage Bioscience Catalyst. The new site is also inside the “golden triangle, ” which is described as the area between the biotech and research hubs of London, Cambridge and Oxford. This facility is set to be built alongside GSK’s existing global R&D facility in the catalyst.
The facility will provide office, lab and manufacturing space to life science companies from early-stage to commercialization. Construction of the facility is slated to begin later this year, and the first phase is set to be completed by the end of 2025.
The campus will consist of 15 buildings and will be called the Elevate Quarter. The project is estimated to create around 5,000 jobs.
“Situated alongside one of our global R&D hubs, this is a really positive development for the sector and it’s great that we’re one step closer to work starting on the new Stevenage development,” said GSK’s chief scientific officer Tony Wood in a release .
UBS and Reef are also redeveloping another property in Stevenage, a former shopping center called The Forum, into 400,000 square feet of life sciences manufacturing space. Approval for that project was given in February this year. UK life science
